CJC-1295 With And Without DAC 2: Complete Guide
CJC-1295 With And Without DAC 2: Complete Guide
CJC-1295 With and Without DAC 2: Complete Guide
What is CJC-1295
CJC-1295 is a synthetic growth hormone releasing peptide (GHRP) designed to stimulate the pituitary gland to secrete more endogenous growth hormone (GH). Unlike older analogs, it mimics the natural secretion pattern of GH, promoting gradual and sustained increases rather than spikes. Its primary function is to support tissue repair, muscle growth, fat loss, and overall metabolic health.
The Study & Development
Research on CJC-1295 began in the early 2000s as part of a broader effort to create safer, more effective GHRPs. Initial preclinical trials demonstrated its ability to elevate GH levels without triggering significant side effects commonly seen with older analogs. Subsequent studies focused on optimizing stability and bioavailability, leading to the development of the DAC (Drug Affinity Complex) version that extends half-life and improves therapeutic potential.
What’s the difference? With V.S. Without!
The core distinction lies in the presence of a Drug Affinity Complex, or DAC.
Without DAC: The peptide has a relatively short half-life (about 3–4 hours). Users typically require multiple daily injections to maintain desired GH levels.
With DAC: The addition of a fatty acid chain binds CJC-1295 to albumin in the bloodstream, dramatically extending its half-life to around 8–12 days. This allows for once-weekly dosing while still delivering consistent growth hormone stimulation.
Pairing CJC-1295 with DAC and Ipamorelin
Combining DAC-modified CJC-1295 with a complementary peptide such as Ipamorelin creates a synergistic effect.
CJC-1295 With And Without DAC 2: Complete Guide
CJC-1295 With and Without DAC 2: Complete Guide
What is CJC-1295
CJC-1295 is a synthetic growth hormone releasing peptide (GHRP) designed to stimulate the pituitary gland to secrete more endogenous growth hormone (GH). Unlike older analogs, it mimics the natural secretion pattern of GH, promoting gradual and sustained increases rather than spikes. Its primary function is to support tissue repair, muscle growth, fat loss, and overall metabolic health.
The Study & Development
Research on CJC-1295 began in the early 2000s as part of a broader effort to create safer, more effective GHRPs. Initial preclinical trials demonstrated its ability to elevate GH levels without triggering significant side effects commonly seen with older analogs. Subsequent studies focused on optimizing stability and bioavailability, leading to the development of the DAC (Drug Affinity Complex) version that extends half-life and improves therapeutic potential.
What’s the difference? With V.S. Without!
The core distinction lies in the presence of a Drug Affinity Complex, or DAC.
Without DAC: The peptide has a relatively short half-life (about 3–4 hours). Users typically require multiple daily injections to maintain desired GH levels.
With DAC: The addition of a fatty acid chain binds CJC-1295 to albumin in the bloodstream, dramatically extending its half-life to around 8–12 days. This allows for once-weekly dosing while still delivering consistent growth hormone stimulation.
Pairing CJC-1295 with DAC and Ipamorelin
Combining DAC-modified CJC-1295 with a complementary peptide such as Ipamorelin creates a synergistic effect.